(20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP SOLUTION
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
10-12-2018
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
SODIUM CHLORIDE; POTASSIUM CHLORIDE
Available from:
BAXTER CORPORATION
ATC code:
B05BB01
INN (International Name):
ELECTROLYTES
Dosage:
900MG; 150MG
Pharmaceutical form:
SOLUTION
Composition:
SODIUM CHLORIDE 900MG; POTASSIUM CHLORIDE 150MG
Administration route:
INTRAVENOUS
Units in package:
1000ML
Prescription type:
Ethical
Therapeutic area:
REPLACEMENT PREPARATIONS
Product summary:
Active ingredient group (AIG) number: 0213340001; AHFS:
Authorization status:
APPROVED
Authorization date:
2012-12-07
Summary of Product characteristics
Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 1 of 15_
PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION, USP
IN PLASTIC CONTAINER
VIAFLEX
Container
20mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
40mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
SOLUTION FOR INFUSION
Solutions Affecting the Electrolyte Balance
BAXTER CORPORATION
Mississauga, ON L5N 0C2
Date of Revision:
December 10, 2018
Control No. 221539
Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 2 of 15_
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
INSTRUCTIONS FOR USE AND HANDLING AND DISPOSAL
................................11
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
......................11
OVERDOSE
......................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
Potassium Chloride in 0.9% Sodium Chlo
Read the complete document
